Bristol-Myers Squibb
As on 11 Oct, 2025 | 01:17 IST
| Open | 44.78 |
| Previous Close | 44.68 |
| Beta | 0.28 |
| High | 44.57 |
| Low | 43.77 |
| TTM EPS See historical trend | 6.73(+391.24% YoY) |
| 52 Week High | 63.14 |
| 52 Week Low | 43.01 |
| TTM PE See historical trend | 6.55(Low PE) |
| Mkt. Cap ($ Billion) | 89.38 |
| Dividend Yield | 5.31 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
| Days | |
|---|---|
| 5 | 44.59 |
| 10 | 45.06 |
| 20 | 45.08 |
| 50 | 46.2 |
| 100 | 46.89 |
| 200 | 51.17 |
Returns
| 1 Week | -2.89% | |
| 1 Month | -6.53% | |
| 3 Months | -9.19% | |
| YTD | -22.08% | |
| 1 Year | -15.96% | |
| 3 Years | -35.65% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 835.87 | -2.28 | 794.72 | 51.76 | 16.15 | 0.74 | 935.37/623.99 | 10.75 | Very Bullish |
| J&J | 191.04 | -0.02 | 460.36 | 19.10 | 10.00 | 3.29 | 192.07/141.30 | 8.70 | Very Bullish |
| AbbVie | 231.55 | 0.37 | 409.18 | 21.86 | 10.59 | 3.49 | 244.80/163.83 | 9.41 | Very Bullish |
| Abbott | 132.68 | -0.47 | 230.13 | 27.08 | 4.90 | 1.71 | 141.07/110.89 | 2.56 | Bearish |
| Merck | 86.29 | -1.38 | 218.54 | 11.29 | 7.64 | 4.04 | 111.57/73.35 | 2.68 | Very Bullish |
Market news
- Wall Street closes higher, boosted by healthcare as investors shrug off jobs data, US shutdownOctober 2, 2025 8:05 AM
- Wall Street ends streak of weekly gains, yields rise as investors digest dataSeptember 27, 2025 8:50 AM
- Stocks finish week higher; Wall Street at record highsSeptember 20, 2025 7:43 AM
- Nasdaq notches record high close, traders look to Fed meetingSeptember 13, 2025 9:16 AM
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.